Clinical Trial Detail

NCT ID NCT03091257
Title A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Massachusetts General Hospital
Indications

multiple myeloma

Therapies

Dabrafenib + Trametinib

Dabrafenib

Trametinib

Age Groups: senior adult

Additional content available in CKB BOOST